Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

PARIS, France – January 23, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced that seven scientific abstracts on its lead drug candidate, obefazimod, [an investigational, orally administered, once-daily small molecule] in clinical development for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at The European Crohn’s and Colitis Organization’s (ECCO’s) 20th Annual Congress as part of scientific exchange, taking place February 19-22, 2025, in Berlin, Germany.

“With 7 abstracts accepted for presentation at ECCO 2025, we look forward to our continued exchange with the inflammatory bowel disease community around the emerging clinical profile of obefazimod,” said Fabio Cataldi, MD, Chief Medical Officer of Abivax.

For more information, see congress details on the ECCO website, and visit the Abivax booth at the ECCO exhibitor hall (booth #30).


Obefazimod data to be presented:

Presentation TitleSessionPresenterPresentation/ Session NumberSession HallDate and Time (EDT)
Oral Presentation
"Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QD"

Digital Oral Presentation Session 6

Prof. Silvio Danese, MD, PhD



Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital

Clinical Trials III

Hall A7Friday, February 21, 2025



8:42am to 8:48am

Poster Presentations
"Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study"

Guided Poster Session

Fernando Magro, MD, PhD



President-Elect of ECCO. Head of the Department of Clinical Pharmacology and Professor of Pharmacology and Therapeutics at University Hospital São João in Porto, Portugal

Poster number: P0636

Hall 2.2Friday, February 21, 2025



12:40pm to 1:40pm

"Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis"

Guided Poster Session

Prof. Séverine Vermeire, MD, PhD



Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study programs conducted and ongoing with obefazimod in UC

Poster number: P0813

Hall 2.2

Friday, February 21, 2025


12:40pm to 1:40pm

"Health-related quality of life (HRQOL) in patients with ulcerative colitis (UC) treated with obefazimod: the phase 2 open-label maintenance study"

Guided Poster Session

Jennifer Fine, ScD
Head of HEOR, Abivax S. A

Poster number: P0840

Hall 2.2

Friday, February 21, 2025



12:40pm to 1:40pm

"Efficacy and safety of obefazimod for the fourth and sixth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): 2-year interim analysis after dose de-escalation to 25 mg"

Guided Poster Session

Prof. Silvio Danese, MD, PhD



Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital

 Hall 2.2

Friday, February 21, 2025



12:40pm to 1:40pm

"Long-term treatment patterns, dose escalation, and steroid use among patients with moderate-to-severe ulcerative colitis using advanced therapies: 3 years of continuous follow-up using IQVIA PharMetrics Plus database"

Guided Poster Session

Prof. Parambir S. Dulai, M.D.



Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois

 Hall 2.2

Friday, February 21, 2025



12:40pm to 1:40pm

"Synergistic reduction of inflammatory cytokines with obefazimod and etrasimod in combination treatment vs. either monotherapy in a mouse model of inflammatory bowel disease"

Guided Poster Session

Didier Scherrer, PhD
Chief Scientific Officer
Abivax S.A.

 Hall 2.2

Friday, February 21, 2025



12:40pm to 1:40pm


About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.


Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.